Assertio to Present at Cantor Virtual Global Healthcare Conference on September 16, 2020
September 09 2020 - 5:02AM
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq:
ASRT), a commercial-stage pharmaceutical company, announced that
the company will present at and participate in investor meetings at
the Cantor Virtual Global Healthcare Conference. President, chief
executive officer and director of Assertio, Todd Smith, will
participate in the fireside chat with analyst Louise Chen on
September 16, 2020 at 2:00 pm ET. The topics to be covered will be
the status of the integration of Zyla Life Sciences, and the
company’s business development strategy, financial results, current
growth trends and milestones over the coming 12 months.
The Cantor Virtual Global Healthcare Conference 2020 will take
place September 15, 16 and 17, 2020. For those interested in
learning more, please visit
https://www.cantor.com/global-healthcare-2020/ for more
information. To listen to the Assertio webcast, please visit the
investor section of the www.assertiotx.com website.
About AssertioAssertio is a leading commercial
pharmaceutical company bringing differentiated products to
patients. The Company has a robust portfolio of branded
prescription products in three areas: neurology, hospital and pain
and inflammation. Assertio has grown through business development
including licensing, mergers and acquisitions. The Company seeks to
leverage its commercial excellence to be the partner of choice. To
learn more about Assertio, visit www.assertiotx.com.
Forward Looking StatementsStatements in this
communication that are not historical facts are forward-looking
statements that reflect Assertio's current expectations,
assumptions and estimates of future performance and economic
conditions. These forward-looking statements are made in reliance
on the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended (the "Securities Act"), and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements relate to, among other things, future events or the
future performance or operations of Assertio. All statements other
than historical facts may be forward-looking statements and can be
identified by words such as "anticipate," "believe," "could,"
"design," "estimate," "expect," "forecast," "goal," "guidance,"
"imply," "intend," "may", "objective," "opportunity," "outlook,"
"plan," "position," "potential," "predict," "project,"
"prospective," "pursue," "seek," "should," "strategy," "target,"
"would," "will," "aim" or other similar expressions that convey the
uncertainty of future events or outcomes are used to identify
forward-looking statements. Such forward-looking statements are not
guarantees of future performance and are subject to risks,
uncertainties and other factors, some of which are beyond the
control of Assertio. Factors that could cause Assertio's actual
results to differ materially from those implied in the
forward-looking statements include: (1) risks related to disruption
of management time from ongoing business operations due to the
integration of the merger with Zyla Life Sciences (the "Merger");
(2) unexpected costs, charges or expenses resulting from the
Merger; (3) the ability of the Assertio to retain key personnel;
(4) potential adverse changes to business relationships resulting
from the Merger; (5) the combined company's ability to achieve the
growth prospects and synergies expected from the transaction, as
well as delays, challenges and expenses associated with integrating
the combined company's existing businesses; (6) negative effects of
the Merger on the market price of Assertio's common stock, credit
ratings and operating results; (7) legislative, regulatory and
economic developments, including changing business conditions in
the industries in which Assertio operates; (8) Assertio's ability
to successfully pursue business development, strategic
partnerships, and investment opportunities to build and grow for
the future; (9) the commercial success and market acceptance of
Assertio's products; (10) coverage of Assertio’s products by payors
and pharmacy benefit managers; (11) Assertio’s ability to execute
on its sales and marketing strategy, including developing
relationships with customers, physicians, payors and other
constituencies; (12) the entry of any generic products for any of
Assertio’s products; (13) the outcome of Assertio’s opioid-related
investigations, Assertio’s opioid-related litigation brought by
state and local governmental entities and private parties, and
Assertio’s insurance, antitrust, securities class action and other
litigation, and the costs and expenses associated therewith; (14)
Assertio's estimates regarding expenses, future revenues, capital
requirements and needs for additional financing; (15) Assertio's
ability to generate sufficient cash flow from its business to make
payments on its indebtedness, Assertio's ability to restructure or
refinance its indebtedness and Assertio's compliance with the terms
and conditions of the agreements governing its indebtedness; (16)
compliance or non-compliance with legal and regulatory requirements
related to the development or promotion of pharmaceutical products
in the U.S.; (17) Assertio's plans to acquire, in-license or
co-promote other products, and/or acquire companies; (18)
Assertio's ability to raise additional capital, if necessary; (19)
variations in revenues obtained from collaborative agreements; (20)
Assertio's collaborative partners' compliance or non-compliance
with obligations under its collaboration agreements; (21) the
ability of Assertio's common stock to regain compliance with
Nasdaq's minimum closing bid requirement of at least $1.00 per
share; (22) the impact of Zyla's bankruptcy and acquisition of
products from Iroko Pharmaceuticals; (23) obtaining and maintaining
intellectual property protection for the Company’s products; (24)
Assertio’s ability to operate its business without infringing the
intellectual property rights of others; (25) the impact of
disasters, acts of terrorism or global pandemics; (26) general
market conditions; and other risks listed in Assertio's filings
with the United States Securities and Exchange Commission ("SEC").
These risks are more fully described in the joint proxy
statement/prospectus filed with the SEC in connection with the
Merger and Assertio's Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the SEC and in other filings
Assertio makes with the SEC from time to time. While Assertio may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to update or
revise any forward-looking-statements contained in this press
release whether as a result of new information or future events,
except as may be required by applicable law.
Media and Investor Contact Dan
Peisertir@assertiotx.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2024 to May 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From May 2023 to May 2024